So......about CATB and my suggestion to take a look. Well, they just missed their primary endpoint in their Phase 2a hypercholesterolemia trial, announced this afternoon. Yet to see how much the share price plunges because CAT-2054 is still viable for other liver indications like NASH, and they still have their CAT-1004 Duchenne muscular dystrophy trial that reads out later in 2016. CATB probably won't plunge as much as RVX did after ASSURE, but still going to take a hit.